Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4

Journal of the National Cancer Institute

Volumn 93, Issue 6, 2001, Pages 436-446

  Soni, Rajeev ^a   O'Reilly, Terence ^a   Furet, Pascal ^a   Muller, Lionel ^a   Stephan, Christine ^a   Zumstein Mecker, Sabine ^a   Fretz, Heinz ^a   Fabbro, Doriano ^a   Chaudhuri, Bhabatosh ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,6 TRIAMINOPYRIMIDINE; CINK 4; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; MUTANT PROTEIN; PROTEIN P16; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSECT; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; STATISTICAL ANALYSIS; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 0035925574     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.6.436     Document Type: Article

References (66)

1. Four-dimensional control of the cell cycle
2. All aboard the cyclin train: Subcellular trafficking of cyclins and their CDK partners
3. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors
4. Cyclin-dependent kinases: Engines, clocks, and microprocessors
5. Cancer cell cycles
6. Inhibitors of mammalian G1 cyclin-dependent kinases
7. The retinoblastoma protein pathway and the restriction point
8. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes
9. The retinoblastoma protein and cell cycle control
10. The regulation of E2F by pRB-family proteins
11. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
12. p16INK4A as a human tumor suppressor
13. Perturbation of cell cycle regulators in human cancer
14. Mutations and altered expression of p16INK4A in human cancer
15. Growth suppression by p16INK4A requires functional retinoblastoma protein
16. Growth suppression by p18, a p16 INK4/MTS1- and p14 INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function
17. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines
18. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study
19. Reciprocal Rb inactivation and p16INK4A expression in primary lung cancers and cell lines
20. Measurement of cdk4 kinase activity using an affinity peptide-tagging technology
21. Regulation of cyclin D- dependent kinase 4 (cdk4) by cdk4-activating kinase
22. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4
23. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2
24. DNA binding protein dbpA binds Cdk5 and inhibits its activity
25. D-type cyclin-dependent kinase activity in mammalian cells
26. Inhibition of cyclin-dependent kinases by p21
27. Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6
28. Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics
29. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine
30. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members
31. Conformational energy penalties of protein-bound ligands
32. Simulation of protein-sugar interactions: A computational model of the complex between ganglioside GM1 and the heat-labile enterotoxin of Escherichia coli
33. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials
34. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitors with potential as an anticancer agent
35. Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex
36. Defining the substrate specificity of cdk4 kinase-cylcin D1 complex
37. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation
38. Evidence for an early G1 ionic event necessary for cell cycle progression and survival in the MCF-7 human breast carcinoma cell line
39. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation
40. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4
41. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics
42. Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels
43. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis
44. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
45. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts
46. A biomarker that identifies senescent human cells in culture and in aging skin in vivo
47. High concentrations of recombinant adenovirus expressing p16 gene induces apoptosis in lung cancer cell lines
48. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
49. The retinoblastoma tumor suppressor protein
50. Regulation of exit from quiescence by p27 and cyclin D1-CDK4
51. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1
52. Tumor suppressor p16INK4A: Determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4
53. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A
54. The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells
55. The inhibitory effect of adenovirus-mediated p16INK4a gene transfer on the proliferation of lung cancer cell line
56. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1
57. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line
58. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence
59. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds
60. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
61. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
62. Characterization of novel inhibitors of cyclin-dependent kinases
63. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule
64. Diaminothiazoles: Potent selective cyclin-dependent kinase inhibitors with antitumor efficacy [abstract]
65. Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas
66. Undersulfation of proteoheparan sulfate stimulates the expression of basic fibroblast growth factor and protein synthesis but suppresses replication of coronary smooth muscle cells